TY  - JOUR
TT  - SARCOMATOID CARCINOMAS OF THE LUNG
AU  - Yanık, Y Fazlı
AU  - Karamustafaoğlu, Yekta Altemur
AU  - Karataş, Adem
AU  - Taştekin, Ebru
AU  - Yörük, Yener
PY  - 2017
DA  - October
JF  - İzmir Göğüs Hastanesi Dergisi
JO  - İzmir Göğüs Dergisi
PB  - İzmir Göğüs Hastalıkları Hastanesi
WT  - DergiPark
SN  - 1300-4115
SP  - 93
EP  - 99
VL  - 31
IS  - 2
KW  - Akciğer
KW  - Kanser
KW  - Sarkomatoid
N2  - Introduction: ‘Sarcomatoid carcinoma of the lung’ is a type of poorly differentiated non-small cell lung cancer which is seen extremely rare (0.3- 1.3 %). Although nearly half of these patients are stage 1 at the time of diagnosis1, the 5-year survival rate is 20 %. Curative surgical treatment supported by adjuvant oncological therapy is important. In this study we aim to presented prognosis and survival of five cases who were diagnosed as sarcomatoid carcinoma of the lung. Material - Methods: We rewieved retrospectively the clinicopathological data of five patients (3 men, 2 women) with a mean age 62.4 ( 47-76 years) with pulmonary sarcomatoid carcinoma who was treated from January 2005 to December 2012 in our clinic. The prognosis and age, sex, smoking history, tumor size, treatment modality and survival was analyzed by patient hospital data. Results: The tumor in three cases located in the right upper lobe, while two cases were in the left lower lobe. In four cases anatomical resection performed, one case is performed only diagnostic “Video-assisted thoracic surgery " because of the advanced stage. All patients died due to metastasis or tumor progression during the follow-up period. Median tumor diameter, survival time, disease-free survival time and length of stay in the hospital were 5.7 ± 1.7 cm (range 3.5 to 8 cm), 8.6±6.9 months (range 2-18 months), 4.8±4.3 months (range 0 -10 months), 5.2 ± 3.9 days (range 4-12 days), respectively. Median SUVmax (Maximum Standardized Uptake Value) value was measured 16.9 ± 11.2 (range 8.5 to 36.2 ) in main tumor. Discussion: Although ‘Sarcomatoid types of lung cancer’ are extremely rare, they have a poor prognosis and their clinical and pathological features have not been fully highlighted. Anatomic resection with curative intent and adjuvant oncologic treatments seems to be only chance for long term survival rates in these cases. In the future, gene studies and immunotherapy can give hope for a new treatment option for this poorprognosis disease. However, we need further studies with larger series of cases about these rare tumors.
CR  - 1. Tellioğlu E, Yücel NC, Ceylan KC, Özacarp R.
Nadir Görülen Bir Akciğer Karsinomu: Dev Hücreli
Karsinom. İzmir Göğüs Hastanesi Dergisi
2011,25(1): 63-67.
CR  - 2. Travis WD, Brambilla E, Nicholson AG, Yatabe Y,
Austin JHM,Beasley MB. The 2015 World Health
Organization Classification ofLung Tumors
Impact of Genetic, Clinical and Radiologic
Advances Since the 2004 Classification. J
Thorac Oncol 2015;10: 1243–1260)
CR  - 3. Corrin B, Chang YL, Rossi G, Koss MN,
Geisinger K, et al. Sarcomatoid Carcinoma. In:
Ed. Travis WD, Brambilla E, Müller-Hermelink
HK, Haris CC. Pathology & Genetics Tumours of
the Lung, Pleura, Thymus and Heart. Lyon, IARC
Press, 2004. pp. 53-58
CR  - 4. Travis WD. Sarcomatoid neoplasms of the lung
and pleura. Arch Pathol Lab Med 2010;
134:1645–8.
CR  - 5. Hountis P, Moraitis S, Dedeilias P, Ikonomidis P
and Douzinas M. Sarcomatoid lung carcinomas:
a case series. Cases Journal 2009, 2:7900
CR  - 6. Ouziane I, Boutayeb S, Mrabti H, Lalya I, Rimani
M and Errihani H. Sarcomatoid Carcinoma of
the Lung: A Model of Resistance of
Chemotherapy. N Am J Med Sci 2014 Jul; 6(7):
342–345.
CR  - 7. Huang SY, Shen SJ and Li XY. Pulmonary
sarcomatoid carcinoma: a clinicopathologic study
and prognostic analysis of 51 cases. World Journal
of Surgical Oncology 2013, 11: 252.
CR  - 8. Steuer CE, Behera M, Liu Y, Fu C,Gillespie TW,
Saba NF et al. Pulmonary sarcomatoid carcinoma:
An analysis of the National Cancer Database. J
Clin Oncol 2015; 33: (suppl; abstr 7537)
CR  - 9. Gu L, Xu Y, Chen Z, Pan Y, Lu S. Clinical analysis
of 95 cases of pulmonary sarcomatoid
carcinoma. Biomed Pharmacother 2015;76:
134-40.
CR  - 10. Vieira T, Duruisseaux M, Ruppert AM, Cadranel
J, Antoine M, Wislez M. Pulmonary sarcomatoid
carcinoma. Bull Cancer 2012; 99(10):995-
1001.
CR  - 11. Rapicetta C, Lococo F, Stefani A, Rossi G,
Ricchetti T, Filice A, Franceschetto A, Treglia G,
Paci M Primary Sarcomatoid Carcinoma of the
Lung: Radiometabolic ((18)F-FDG PET/CT)
Findings and Correlation with ClinicoPathological
and Survival Results. Lung. 2016
Aug;194(4):653-7.
CR  - 12. Pelosi G, Sonzogni A, De Pas T, Galetta D,
Veronesi G, Spaggiari L, Manzotti M, Fumagalli
C, Bresaola E, Nappi O, Viale G, Rosai
J.Pulmonary Sarcomatoid Carcinomas: A
Practical OverviewInt J Surg Pathol 2010
Apr;18(2):103-20.
CR  - 13. Terra SB, Jang JS, Bi L, Kipp BR, Jen J, Yi ES,
Boland JM Molecular characterization of
pulmonary sarcomatoid carcinoma: analysis of
33 cases. Mod Pathol 2016 Aug;29(8):824-31.
CR  - 14. Shum E, Stuart M, Borczuk A, Wang F, Cheng
H, Halmos B. Recent advances in the management
of pulmonary sarcomatoid carcinoma.
Expert Rev Respir Med 2016;10:1-10.
CR  - 15. Vieira T, Antoine M, Hamard C, Fallet V,
Duruisseaux M, Rabbe N, Rodenas A, Cadranel
J, Wislez M. Sarcomatoid lung carcinomas
show high levels of programmed death ligand1
(PD-L1) and strong immune-cell infiltration
by TCD3 cells and macrophages. Lung Cancer
2016;98:51-8.
UR  - https://dergipark.org.tr/tr/pub/ighd/article/523321
L1  - https://dergipark.org.tr/tr/download/article-file/643167
ER  -